Lupin is currently trading at Rs. 612.90, up by 1.50 points or 0.25% from its previous closing of Rs. 611.40 on the BSE.
The scrip opened at Rs. 614.00 and has touched a high and low of Rs. 618.20 and Rs. 608.75 respectively. So far 17175 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1193.00 on 20-Jul-2021 and a 52 week low of Rs. 583.05 on 25-May-2022.
Last one week high and low of the scrip stood at Rs. 640.70 and Rs. 607.40 respectively. The current market cap of the company is Rs. 27795.68 crore.
The promoters holding in the company stood at 46.78%, while Institutions and Non-Institutions held 41.85% and 11.37% respectively.
Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Paliperidone Extended-Release Tablets 1.5 mg, 3 mg, 6 mg, and 9 mg, to market a generic equivalent of Invega Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg, of Janssen Research and Development, LLC. The product will be manufactured at Lupin’s facility in Goa, India. Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of $152 million in the U.S. (IQVIA MAT March 2022).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1858.70 |
Dr. Reddys Lab | 1258.55 |
Cipla | 1559.20 |
Lupin | 2198.25 |
Zydus Lifesciences | 1004.00 |
View more.. |